Macrolide therapy in chronic inflammatory diseases

Mediators of Inflammation

Volumn 2012, Issue , 2012, Pages

  Kwiatkowska, Brygida ^a   Maliska, Maria ^a  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CYCLOOXYGENASE 2; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; ERYTHROMYCIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; PIMECROLIMUS; PROTON PUMP INHIBITOR; RAPAMYCIN; RIFABUTIN; RIFAMPICIN; ROXITROMYCIN; TACROLIMUS; TETRACYCLINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTHRITIS; ATOPIC DERMATITIS; CHLAMYDIAL PNEUMONIA; CHRONIC DISEASE; CLINICAL PRACTICE; CONJUNCTIVITIS; CROHN DISEASE; DRUG EFFICACY; ENTERITIS; HELICOBACTER INFECTION; HUMAN; IMMUNOREGULATION; INFLAMMATORY DISEASE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; QT PROLONGATION; REACTIVE ARTHRITIS; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SKIN DISEASE; TORSADE DES POINTES; TRACHOMA; ANIMAL; INFLAMMATION;

NEGIBACTERIA;

ANIMALS; ANTI-BACTERIAL AGENTS; CHRONIC DISEASE; ERYTHROMYCIN; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; MACROLIDES;

EID: 84866060867     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2012/636157     Document Type: Review

References (64)

1. Alekshun M. N., New advances in antibiotic development and discovery. Expert Opinion on Investigational Drugs 2005 14 2 117 134 2-s2.0-12744268873 10.1517/13543784.14.2.117 (Pubitemid 40403388)
2. Wilson D. N., The A-Z of bacterial translation inhibitors. Critical Reviews in Biochemistry and Molecular Biology 2009 44 393 433 10.3109/10409230903307311
3. Douthwaite S., Hansen L. H., Mauvais P., Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23S rRNA. Molecular Microbiology 2000 36 1 183 192 2-s2.0-0034115717 10.1046/j.1365-2958.2000.01841.x (Pubitemid 30195400)
4. Katzung B.G Macrolides, Basic & Clinical Pharmacology 2004 44 9th
5. Suzaki H., Asano K., Ohki S., Kanai K., Mizutani T., Hisamitsu T., Suppressive activity of a macrolide antibiotic, roxithromycin, on pro-inflammatory cytokine production in vitro and in vivo. Mediators of Inflammation 1999 8 4-5 199 204 2-s2.0-0033385193 10.1080/09629359990351 (Pubitemid 30019329)
6. Shimane T., Asano K., Suzuki M., Hisamitsu T., Suzaki H., Influence of a macrolide antibiotic, roxithromycin, on mast cell growth and activation in vitro. Mediators of Inflammation 2001 10 6 323 332 2-s2.0-0035691497 10.1080/09629350120102343 (Pubitemid 34084412)
7. Schultz M. J., Speelman P., Hack C. E., Buurman W. A., Van Deventer S. J. H., Van Der Poll T., Intravenous infusion of eryhtromycin inhibits CXC chemokine production, but augments neutrophil degranulation in whole blood stimulated with Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy 2000 46 2 235 240 2-s2.0-0033624163 (Pubitemid 30642517)
8. Matsuoka N., Eguchi K., Kawakami A., Tsuboi M., Kawabe Y., Aoyagi T., Nagataki S., Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clinical and Experimental Immunology 1996 104 3 501 508 2-s2.0-0030063950 (Pubitemid 26000377)
9. Takizawa H., Desaki M., Ohtoshi T., Kawasaki S., Kohyama T., Sato M., Tanaka M., Kasama T., Kobayashi K., Nakajima J., Ito K., Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. American Journal of Respiratory and Critical Care Medicine 1997 156 1 266 271 2-s2.0-0345461567 (Pubitemid 27293200)
10. Nelson S., Summer W. R., Terry P. B., Warr G. A., Jakab G. J., Erythromycin-induced suppression of pulmonary antibacterial defenses. A potential mechanism of superinfection in the lung. American Review of Respiratory Disease 1987 136 5 1207 1212 2-s2.0-0023200899 (Pubitemid 17151089)
11. Keicho N., Kudoh S., Yotsumoto H., Akagawa K. S., Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. Journal of Antibiotics 1993 46 9 1406 1413 2-s2.0-0027452041 (Pubitemid 23290989)
12. Keicho N., Kudoh S., Yotsumto H., Akagawa K. S., Erythromycin promotes monocyte to macrophage differentiation. Journal of Antibiotics 1994 47 1 80 89 2-s2.0-0028107633 (Pubitemid 24045528)
13. Yamamoto K., Arakawa T., Ueda N., Yamamoto S., Transcriptional roles of nuclear factor κ B and nuclear factor-interleukin-6 in the tumor necrosis factor α -dependent induction of cyclooxygenase-2 in MC3T3-E1 cells. The Journal of Biological Chemistry 1995 270 52 31315 31320 2-s2.0-0029595394
14. Ianaro A., Ialenti A., Maffia P., Sautebin L., Rombolà L., Carnuccio R., Iuvone T., D'Acquisto F., Di Rosa M. D., Anti-inflammatory activity of macrolide antibiotics. Journal of Pharmacology and Experimental Therapeutics 2000 292 1 156 163 2-s2.0-0033971290 (Pubitemid 30026366)
15. Kohyama T., Takizawa H., Kawasaki S., Akiyama N., Sato M., Ito K., Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. Antimicrobial Agents and Chemotherapy 1999 43 4 907 911 2-s2.0-0032925065 (Pubitemid 29165756)
16. Sato E., Nelson D. K., Koyama S., Hoyt J. C., Robbins R. A., Erythromycin modulates eosinophil chemotactic cytokine production by human lung fibroblasts in vitro. Antimicrobial Agents and Chemotherapy 2001 45 2 401 406 2-s2.0-0035139643 10.1128/AAC.8.2.401-406.2001 (Pubitemid 32105272)
17. Williams A. C., Galley H. F., Watt A. M., Webster N. R., Differential effects of three antibiotics on T helper cell cytokine expression. Journal of Antimicrobial Chemotherapy 2005 56 3 502 506 2-s2.0-24644439165 10.1093/jac/dki251 (Pubitemid 41264127)
18. Sugiyama K., Shirai R., Mukae H., Ishimoto H., Nagata T., Sakamoto N., Ishii H., Nakayama S., Yanagihara K., Mizuta Y., Kohno S., Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clinical and Experimental Immunology 2007 147 3 540 546 2-s2.0-33846837316 10.1111/j.1365-2249.2007.03299.x (Pubitemid 46208057)
19. Kanoh S., Rubin B. K., Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clinical Microbiology Reviews 2010 23 3 590 615 2-s2.0-77954595517 10.1128/CMR.00078-09
20. Nakamura H., Fujishima S., Inoe T., Clinical and immunomodulatory effects of roxitromycin therapy for chronic respiratory tract infection. European Respiratory Society 1999 13 1371 1379 10.1183/09031936.99.13613809 (Pubitemid 29357155)
21. Aoshiba K., Nagai A., Konno K., Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrobial Agents and Chemotherapy 1995 39 4 872 877 2-s2.0-0028903792
22. Inamura K., Ohta N., Fukase S., Kasajima N., Aoyagi M., The effects of erythromycin on human peripheral neutrophil apoptosis. Rhinology 2000 38 3 124 129 2-s2.0-0033808917
23. Oyama T., Sakuta T., Matsushita K., Maruyama I., Nagaoka S., Torii M., Effects of roxithromycin on tumor necrosis factor-alpha-induced vascular endothelial growth factor expression in human periodontal ligament cells in culture. Journal of Periodontology 2000 71 10 1546 1553 2-s2.0-0033736369
24. Fumimori T., Honda S., Migita K., Hamada M., Yoshimuta T., Honda J., Fukuda T., Suzuki R., Gotoh M., Eguchi K., Aizawa H., Erythromycin suppresses the expression of cyclooxygenase-2 in rheumatoid synovial cells. Journal of Rheumatology 2004 31 3 436 441 2-s2.0-12144289353 (Pubitemid 38337599)
25. Terao H., Asano K., Kanai K. I., Kyo Y., Watanabe S., Hisamitsu T., Suzaki H., Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice. Mediators of Inflammation 2003 12 4 195 202 2-s2.0-0142125230 10.1080/09629350310001599620 (Pubitemid 37297187)
26. Kohri K., Tamaoki J., Kondo M., Aoshiba K., Tagaya E., Nagai A., Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. European Respiratory Journal 2000 15 1 62 67 2-s2.0-0033979366 10.1034/j.1399-3003.2000.15a12.x (Pubitemid 30068937)
27. Garry K. W., Rubinstein I., Gotfried M. H., Khan I. J., Varma S., Danziger L. H., Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma. Chest 2000 118 6 1826 1827 2-s2.0-0034544739 10.1378/chest.118.6.1826 (Pubitemid 32001818)
28. Shinkai M., Henke M. O., Rubin B. K., Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacology and Therapeutics 2008 117 3 393 405 2-s2.0-39549115019 10.1016/j.pharmthera.2007.11. 001
29. Keicho N., Kudoch S., Diffuse panbronchiolotis:role of macrolides therapy. American Journal of Respiratory Medicine 2002 1 2 119 131
30. Enomoto T., Azuma A., Sakakibara K., Usuki J., Kudo S., Azithromycin therapy for patients with intractable diffuse panbronchiolitis. The Japanese journal of antibiotics 2003 56 supplement A 12 14 2-s2.0-1542394261
31. Vanaudenaerde B. M., Vos R., Meyts I., de Vleeschauwer S. I., Verleden S. E., Widyastuti-Willems A., Wuyts W. A., Van Raemdonck D. E., Hoet P. H., Dupont L. J., Nemery B., Verleden G. M., Macrolide therapy targets a specific phenotype in respiratory medicine: from clinical experience to basic science and back. Inflammation and Allergy 2008 7 4 279 287 2-s2.0-58249087106 10.2174/187152808786848414
32. Gianni L. M., Sulli M. M., Topical tacrolimus in the treatment of atopic dermatitis. Annals of Pharmacotherapy 2001 35 7-8 943 946 2-s2.0-0034916169 (Pubitemid 32678721)
33. Standaert R. F., Galat A., Verdine G. L., Schreiber S. L., Molecular cloning and overexpression of the human FK506-binding protein FKBP. Nature 1990 346 6285 671 674 2-s2.0-0025061678 10.1038/346671a0 (Pubitemid 20266403)
34. Nghiem P., Pearson G., Langley R. G., Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. Journal of the American Academy of Dermatology 2002 46 2 228 241 2-s2.0-0036165478 10.1067/mjd.2002.120942 (Pubitemid 34118380)
35. Komine M., Tamaki K., An open trial of oral macrolide treatment for psoriasis vulgaris. Journal of Dermatology 2000 27 8 508 512 2-s2.0-0033812120
36. Polat M., Lenk N., Yalcin B., Gür G., Tamer E., Artuz F., Alli N., Efficacy of erythromycin for psoriasis vulgaris. Clinical and Experimental Dermatology 2007 32 3 295 297 2-s2.0-33947666029 10.1111/j.1365-2230.2007.02370. x (Pubitemid 46495798)
37. Gui G. P. H., Thomas P. R. S., Tizard M. L. V., Lake J., Sanderson J. D., Hermon-Taylor J., Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. Journal of Antimicrobial Chemotherapy 1997 39 3 393 400 2-s2.0-0030906446 10.1093/jac/39.3.393 (Pubitemid 27153799)
38. Inoue S., Nakase H., Matsuura M., Open label trial of claritromycin therapy in Japanese patients with Crohn's disease. Journal of Gastroenterology and Hepatology 2007 22 984 10.1111/j.1440-1746.2006.04533.x (Pubitemid 47019847)
39. Chuah S. K., Tsay F. W., Hsu P. I., Wu D. C., A new look at anti-Helicobacter pylori therapy. World Journal of Gastroenterology 2011 17 35 3971 3975
40. Itoh Z., Suzuki T., Nakaya M., Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut. Antimicrobial Agents and Chemotherapy 1984 26 6 863 869 2-s2.0-0021744529 (Pubitemid 15181380)
41. Catnach S. M., Fairclough P. D., Erythromycin and the gut. Gut 1992 33 3 397 401 2-s2.0-0026557365
42. Mentec H., Dupont H., Bocchetti M., Cani P., Ponche F., Bleichner G., Upper digestive intolerance during enteral nutrition in critically ill patients: frequency, risk factors, and complications. Critical Care Medicine 2001 29 10 1955 1961 2-s2.0-0034780645 (Pubitemid 32980408)
43. Hawkyard C. V., Koerner R. J., The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: benefits versus risks. Journal of Antimicrobial Chemotherapy 2007 59 3 347 358 2-s2.0-34247370872 10.1093/jac/dkl537 (Pubitemid 47073441)
44. Furst D. E., Saag K., Fleischmann M. R., Sherrer Y., Block J. A., Schnitzer T., Rutstein J., Baldassare A., Kaine J., Calabrese L., Dietz F., Sack M., Senter R. G., Wiesenhutter C., Schiff M., Stein C. M., Satoi Y., Matsumoto A., Caldwell J., Harris R. E., Moreland L. W., Hurd E., Yocum D., Stamler D. A., Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis and Rheumatism 2002 46 8 2020 2028 2-s2.0-0036674871 10.1002/art.10427
45. Migita K., Eguchi K., Aoyagi T., Tsukada T., Tsuboi M., Kawabe Y., Nagataki S., The effects of the immunosuppressant rapamycin on the growth of rheumatoid arthritis (RA) synovial fibroblast. Clinical and Experimental Immunology 1996 104 1 86 91 2-s2.0-0030012736 (Pubitemid 26103416)
46. Ogrendik M., Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial. Clinical Therapeutics 2009 31 8 1754 1764 2-s2.0-72149122383 10.1016/j.clinthera.2009.08.014
47. Ogrednik M., Effects of clarithromycin in patients with active rheumatoid arthritis. Current Medical Research and Opinion 2007 23 515 522 10.1185/030079906X167642 (Pubitemid 46456899)
48. Ogrendik M., Karagoz N., Treatment of rheumatoid arthritis with roxithromycin: a randomized trial. Postgraduate Medicine 2011 123 220 227 10.3810/pgm.2011.09.2478
49. Carter J. D., Valeriano J., Vasey F. B., Doxycycline versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to Chlamydia-induced arthritis. A prospective, randomized 9-month comparison. Journal of Rheumatology 2004 31 10 1973 1980 2-s2.0-5044234115 (Pubitemid 39336722)
50. Dreses-Werringloer U., Padubrin I., Zeidler H., Köhler L., Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. Antimicrobial Agents and Chemotherapy 2001 45 11 3001 3008 2-s2.0-0034769879 10.1128/AAC.45.11.3001-3008.2001 (Pubitemid 32988820)
51. Bin X. X., Wolf K., Schaffner T., Malinverni R., Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice. Antimicrobial Agents and Chemotherapy 2000 44 6 1761 1764 2-s2.0-0343362694 10.1128/AAC.44.6.1761- 1764.2000 (Pubitemid 30340837)
52. Denis F., Chaumeil C., Goldschmidt P., Delval L., Pouliquen P., Cochereau I., Chainier D., De Barbeyrac B., Microbiological efficacy of 3-day treatment with azithromycin 1.5 eyedrops for purulent bacterial conjunctivitis. European Journal of Ophthalmology 2008 18 6 858 868 2-s2.0-58149376740
53. West S. K., Munoz B., Mkocha H., Gaydos C. A., Quinn T. C., Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania. Journal of Infectious Diseases 2011 204 2 268 273 2-s2.0-79958732561 10.1093/infdis/jir257
54. Jang Y. J., Kwon H. J., Lee B. J., Effect of clarithromycin on rhinovirus-16 infection in A549 cells. European Respiratory Journal 2006 27 1 12 19 2-s2.0-30744451971 10.1183/09031936.06.00008005 (Pubitemid 43092661)
55. Suzuki T., Yamaya M., Sekizawa K., Hosoda M., Yamada N., Ishizuka S., Yoshino A., Yasuda H., Takahashi H., Nishimura H., Sasaki H., Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells. American Journal of Respiratory and Critical Care Medicine 2002 165 8 1113 1118 2-s2.0-0037090809 (Pubitemid 34415820)
56. Beigelman A., Mikols C. L., Gunsten S. P., Cannon C. L., Brody S. L., Walter M. J., Azithromycin attenuates airway inflammation in a mouse model of viral bronchiolitis. Respiratory Research 2010 11 article 90 2-s2.0-77956707732 10.1186/1465-9921-11-90
57. Yamaya M., Shinya K., Hatachi Y., Kubo H., Asada M., Yasuda H., Nishimura H., Nagatomi R., Clarithromycin inhibits type A seasonal influenza virus infection in human airway epithelial cells. Journal of Pharmacology and Experimental Therapeutics 2010 333 1 81 90 2-s2.0-77949741612 10.1124/jpet.109.162149
58. Eisen H. J., Tuzcu E. M., Dorent R., Kobashigawa J., Mancini D., Valantine-Von Kaeppler H. A., Starling R. C., Sorensen K., Hummel M., Lind J. M., Abeywickrama K. H., Bernhardt P., Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. The New England Journal of Medicine 2003 349 9 847 858 2-s2.0-19244366021 10.1056/NEJMoa022171 (Pubitemid 37025404)
59. Mencarelli A., Distrutti E., Renga B., Cipriani S., Palladino G., Booth C., Tudor G., Guse J. H., Hahn U., Burnet M., Fiorucci S., Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis. European Journal of Pharmacology 2011 665 13 29 39 2-s2.0-79958267558 10.1016/j.ejphar.2011.04.036
60. Blagosklonny M.V Progeria, Rapamycin and normal aging: recent breakthrough. AGING 2011 3 7 685 691
61. Gascon P. M., Dayer P., Comparative effects of macrolide antibiotics on liver mono-oxygenases. Abstract. Clinical Pharmacology & Therapeutics 1991 49 158
62. Von Rosenstiel N. A., Adam D., Macrolide antibacterials: drug interactions of clinical significance. Drug Safety 1995 13 2 105 122 2-s2.0-0029130840
63. Westphal J. F., Macrolide-Induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. British Journal of Clinical Pharmacology 2000 50 4 285 295 2-s2.0-0033770638 10.1046/j.1365-2125.2000.00261.x
64. Gomes T., Mamdani M. M., Juurlink D. N., Macrolide-induced digoxin toxicity: a population-based study. Clinical Pharmacology and Therapeutics 2009 86 4 383 386 2-s2.0-70349440960 10.1038/clpt.2009.127